Skip to content

The mechanism of RPTOR regulating brain metastasis of lung adenocarcinoma along the SpHK2 /SIP/STAT3 axis

The mechanism of RPTOR regulating brain metastasis of lung adenocarcinoma along the SpHK2 /SIP/STAT3 axis

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100043409
Enrollment
Unknown
Registered
2021-02-15
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung adenocarcinoma

Interventions

simple lung adenocarcinoma group vs brain metastasis group:Nil

Sponsors

Fujian Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. The newly diagnosed patients with lung adenocarcinoma diagnosed by pathology had no metastasis to other distant target organs and were classified as the simple lung adenocarcinoma group. 2. For newly diagnosed patients with lung adenocarcinoma diagnosed by pathology, with or without symptoms and signs of brain metastasis,MRI and CT indicated single and multiple lesions in the brain, excluding other conditions, brain metastasis of lung adenocarcinoma can be diagnosed. 3. Aged > 18 years. 4. ECOG score 0-2. 5. At least one measurable lesion. 6. Understand the condition and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Except those without pathological evidence and untraceable follow-up. 2. Unless the primary lesion is unknown or other tumors are combined within the last 2 years. 3. Except for patients who cannot be treated with lung adenocarcinoma. 4. Expected survival time with other serious life-threatening diseases.Except for patients in March. 5. Except for pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
drive gene events of brain metastasis;

Countries

China

Contacts

Public ContactHongru Li

Fujian Provincial Hospital

muzi131122@163.com+86 13665066721

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026